GENE ONLINE|News &
Opinion
Blog

2020-09-22| Special

Spotlight: Cannabidiol (CBD) Based Medication Heralds New Promise in Neurological Therapies

by GeneOnline
Share To
Among the 100 or so phytocannabinoids that have been identified in the Cannabis sativa herb, delta 9-tetrahydrocannabinol (THC) and cannabidiol (CBD) have been explored the most for pharmacological use. Although 33 states have approved the use of cannabis in the U.S. for medicinal purposes, the U.S. Drug Enforcement Administration recognizes it as a Schedule I drug.

This has impeded the use of cannabis in clinical research, potentially obscuring physicians and nurses about its safety, efficacy, and dosage for pharmaceutical applications through rigorous double-blinded, placebo-controlled studies. Besides, cannabinoid-containing substances obtained for research purposes are not chemically or physically representative of the legal cannabis market.

GO Prime with only $1.49 now

LATEST
Axsome’s AXS-05 Achieves Endpoints In Alzheimer’s Agitation Trial
2022-11-29
Spectrum to Cut 75% of Staff and NSCLC Program Following CLR
2022-11-28
Full-Life Technologies to Acquire Focus-X Therapeutics, Bolstering Peptide-Focused Radiopharmaceutical Pipeline
2022-11-28
Medeologix Acquires Three Silicon Valley Medical Device CDMO Companies and Establishes One-Stop Shop Mass Production Facilities in Taiwan
2022-11-28
GenFleet Therapeutics to Present Data from Phase I Trial of GFH009 Monotherapy at the 2022 Annual Meeting of American Society of Hematology (ASH)
2022-11-28
Everest’s Renal Drug Gets Placed On Fast Track For Approval In Taiwan And Korea
2022-11-28
Canada Authorizes Roche’s Polivy as First-Line Lymphoma Treatment
2022-11-27
EVENT
2022-12-01
BIOCHINA 2022
Online
2022-12-10
64TH ASH ANNUAL MEETING & EXPOSITION
New Orleans, USA
2022-12-14
BIOHK2022
Hong Kong, China
2023-01-07
7th Asia Microbiome Conference
Taipei, Taiwan
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!